Government rules changed to ensure availability of GLP-1 RAs 5 June 2024 From this week, Government rules have been changed to ensure medicines like Ozempic and Trulicity are available for the people who need them most. These medicines are called glucagon-like peptide 1 receptor agonists or GLP-1 RAs. When the government began subsidising GLP-1 RAs they could only be available if you were being treated with other diabetes medicines (like metformin, insulin, etc) and the other medicines weren’t working to reduce your blood glucose, or you had a reaction. However, data shows that people were being prescribed GLP-1 RAs outside of these rules. In order to deal with this, the rules have been changed to: Increase access by only requiring one other medicine to have been tried (e.g. metformin), and Require doctors to get phone authorization before they can prescribe GLP-1 RAs to new users. If you’re already on Ozempic or another GLP-1 RA and it is funded through the government, these new rules shouldn’t affect you. We know that GLP-1 RAs are in short supply, and we don’t think these rules will have an immediate effect on your ability to get access to these medicines. More information is available from the PBS website.
Blog 3 August 2026 The Diabetes Connection: Free community event coming to Orange A free community event helping Central West communities learn more about diabetes, reduce their risk, and take positive steps towards better health. Continue Reading
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading
Blog 22 July 2026 Living Out Loud: how Australia spoke up for National Diabetes Week 2026 From 12 to 18 July, Australians living with diabetes, alongside their carers, researchers, health professionals and clinicians, did something powerful. They... Continue Reading